Samsung Pharm Cash Flow Conversion Efficiency

Latest as of September 2025: -0.013x

Samsung Pharm cash flow conversion efficiency. Based on the latest financial reports, Samsung Pharm (001360) has a cash flow conversion efficiency ratio of -0.013x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-2.29 Billion ≈ $-1.55 Million USD) by net assets (₩180.09 Billion ≈ $122.05 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Cash Flow Conversion Efficiency of Samsung Pharm (2012–2024)

Cash flow conversion efficiency of Samsung Pharm from 2012 to 2024. This chart illustrates how Samsung Pharm's cash flow conversion efficiency has evolved over time, based on yearly financial data. View 001360 stock price and chart for real-time trading data and today's change.

Samsung Pharm Cash Flow Conversion Ratio Explained

Samsung Pharm cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.

Samsung Pharm Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Samsung Pharm ranked by their cash flow conversion efficiency. Also see Samsung Pharm market capitalisation for the company's overall valuation and market capitalisation.

Company	Cash Flow Conversion Efficiency
Tat Gida Sanayi AS IS:TATGD	0.249x
Hancock & Gore Ltd AU:HNG	0.013x
Manaksia Steels Limited NSE:MANAKSTEEL	0.090x
Zevia Pbc NYSE:ZVIA	0.003x
Wilmar Cahaya Indonesia Tbk JK:CEKA	-0.075x
Agile Group Holdings Limited F:A8P	0.153x
C-Media Electronics TWO:6237	0.016x
KG Mobilians Co. Ltd KQ:046440	0.072x

Annual Cash Flow Conversion Efficiency for Samsung Pharm (2012–2024)

The table below shows the annual cash flow conversion efficiency of Samsung Pharm from 2012 to 2024. Review 001360 cash flow after capex ratio to assess how much free cash flow the company generates relative to operating cash flow.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	₩105.86 Billion ≈ $71.74 Million	₩-17.30 Billion ≈ $-11.72 Million	-0.163x	+54.17%
2023-12-31	₩77.58 Billion ≈ $52.58 Million	₩-27.66 Billion ≈ $-18.74 Million	-0.356x	-1810.44%
2022-12-31	₩102.59 Billion ≈ $69.52 Million	₩-1.91 Billion ≈ $-1.30 Million	-0.019x	+66.85%
2021-12-31	₩127.27 Billion ≈ $86.25 Million	₩-7.16 Billion ≈ $-4.85 Million	-0.056x	-168.73%
2020-12-31	₩121.92 Billion ≈ $82.62 Million	₩-2.55 Billion ≈ $-1.73 Million	-0.021x	-22.88%
2019-12-31	₩142.83 Billion ≈ $96.79 Million	₩-2.43 Billion ≈ $-1.65 Million	-0.017x	+65.59%
2018-12-31	₩131.66 Billion ≈ $89.23 Million	₩-6.52 Billion ≈ $-4.42 Million	-0.050x	-190.23%
2017-12-31	₩93.87 Billion ≈ $63.61 Million	₩5.15 Billion ≈ $3.49 Million	0.055x	+145.48%
2016-12-31	₩82.38 Billion ≈ $55.83 Million	₩-9.94 Billion ≈ $-6.74 Million	-0.121x	-32.70%
2015-12-31	₩46.24 Billion ≈ $31.33 Million	₩-4.20 Billion ≈ $-2.85 Million	-0.091x	+84.40%
2014-12-31	₩23.29 Billion ≈ $15.79 Million	₩-13.58 Billion ≈ $-9.21 Million	-0.583x	-81.92%
2012-12-31	₩34.71 Billion ≈ $23.52 Million	₩-11.13 Billion ≈ $-7.54 Million	-0.321x	--

About Samsung Pharm

KO:001360 Korea Drug Manufacturers - Specialty & Generic

Market Cap

$76.73 Million

₩113.23 Billion KRW

Market Cap Rank

#20048 Global

#1060 in Korea

Share Price

₩1203.00

Change (1 day)

-2.20%

52-Week Range

₩1180.00 - ₩2210.00

All Time High

₩12289.83